UKRI translation: MRC proof of concept: stage two supports academic teams developing and testing medical interventions from prototypes through early clinical trials to advance patient benefit or commercialisation.
The closing date moved from 4 November 2026 to 3 March 2027 (4:00pm UK time); opening moved from 9 July to 5 November 2026 (9:00am UK time). Eligibility wording also changed, including removal of applications to non-UKRI funders from the uninvited-resubmission restriction.
UKRI Translation: MRC Proof of Concept: stage one supports academic teams developing and testing medical interventions and research tools to address significant health needs and advance patient benefit.
MRC: research grant: applicant-led supports research teams undertaking discovery and early translational work to understand human health and disease, improve diagnosis, advance treatment and prevent illness.
Experimental medicine stage one supports academic researchers conducting human intervention studies to understand disease mechanisms and identify paths towards future treatments or diagnostics.
Experimental medicine: invited stage two application supports academic teams testing disease mechanisms through human interventions to generate insights that could inform future therapies or diagnostics.
MRC: new investigator research grant: applicant-led supports new investigators with discovery and early translational health research to understand disease and build independent research careers.